Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy.

[1]  R. Berkowitz,et al.  Universal Screening for Mismatch-Repair Deficiency in Endometrial Cancers to Identify Patients With Lynch Syndrome and Lynch-like Syndrome , 2016, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[2]  T. Longacre,et al.  Lynch Syndrome Screening in the Gynecologic Tract: Current State of the Art , 2016, The American journal of surgical pathology.

[3]  M. Hitchins.  Finding the needle in a haystack: identification of cases of Lynch syndrome with MLH1 epimutation , 2016, Familial Cancer.

[4]  F. Gao,et al.  Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Pai,et al.  Clinicopathological comparison of colorectal and endometrial carcinomas in patients with Lynch-like syndrome versus patients with Lynch syndrome. , 2015, Human pathology.

[6]  C. Moskaluk,et al.  Clinicopathologic Comparison of Lynch Syndrome–associated and “Lynch-like” Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry , 2015, The American journal of surgical pathology.

[7]  S. Gruber,et al.  Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  W. Frankel,et al.  Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. , 2014, Gastroenterology.

[9]  J. Kench,et al.  Clinical and pathologic features of familial pancreatic cancer , 2014, Cancer.

[10]  R. Pai,et al.  Lynch Syndrome Screening Should Be Considered for All Patients With Newly Diagnosed Endometrial Cancer , 2014, The American journal of surgical pathology.

[11]  R. Broaddus,et al.  Consequences of universal MSI/IHC in screening ENDOMETRIAL cancer patients for Lynch syndrome. , 2014, Gynecologic oncology.

[12]  Stephanie A Cohen,et al.  The Application of Clinical Genetics Dovepress the Genetic Basis of Lynch Syndrome and Its Implications for Clinical Practice and Risk Management , 2022 .

[13]  C. Eng,et al.  Equality in lynch syndrome screening: why should we hold patients with endometrial cancer to a different standard? , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  I. Nagtegaal,et al.  Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors. , 2014, Gastroenterology.

[15]  Alexander M. Metcalf,et al.  Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  F. Aranda,et al.  Prevalence of Lynch Syndrome among Patients with Newly Diagnosed Endometrial Cancers , 2013, PloS one.

[17]  Aung Ko Win,et al.  BRAFV600E Immunohistochemistry Facilitates Universal Screening of Colorectal Cancers for Lynch Syndrome , 2013, The American journal of surgical pathology.

[18]  C. Eng,et al.  Implementation of tumor testing for lynch syndrome in endometrial cancers at a large academic medical center. , 2013, Gynecologic oncology.

[19]  R. Kuiper,et al.  EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients , 2013, Familial Cancer.

[20]  J. Church,et al.  Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Aoki,et al.  Epimutation and cancer: A new carcinogenic mechanism of Lynch syndrome , 2012, International Journal of Oncology.

[22]  H. Hampel,et al.  Endometrial cancer patients and compliance with genetic counseling: room for improvement. , 2011, Gynecologic oncology.

[23]  A. Gill,et al.  Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma , 2010, Pathology.

[24]  Jian-Min Chen.  The 10‐Mb paracentric inversion of chromosome arm 2p in activating MSH2 and causing hereditary nonpolyposis colorectal cancer: Re‐annotation and mutational mechanisms , 2008, Genes, chromosomes & cancer.

[25]  A. Spurdle,et al.  Molecular, Pathologic, and Clinical Features of Early-Onset Endometrial Cancer: Identifying Presumptive Lynch Syndrome Patients , 2008, Clinical Cancer Research.

[26]  R. Hamelin,et al.  Assessment of MLH1 promoter methylation in relation to gene expression requires specific analysis , 2007, Oncogene.

[27]  R. Broaddus,et al.  Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  W. Frankel,et al.  Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. , 2006, Cancer research.